Trial · NCT00940225
Adverse events1,464
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 1,464
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | RDT All Cohorts | 63 | 526 | |
| other | Anaemia | Blood and lymphatic system disorders | NRE Cohort - CRPC 100mg (Castration-Resistant Prostate Cancer) | 29 | 93 | |
| other | Anaemia | Blood and lymphatic system disorders | NRE Cohort - CRPC 39.4mg (Castration-Resistant Prostate Cancer) | 5 | 51 | |
| other | Anaemia | Blood and lymphatic system disorders | NRE Cohort - Ovarian 100mg | 10 | 60 | |
| other | Leukopenia | Blood and lymphatic system disorders | RDT All Cohorts | 27 | 526 | |
| other | Leukopenia | Blood and lymphatic system disorders | NRE Cohort - CRPC 100mg (Castration-Resistant Prostate Cancer) | 7 | 93 | |
| other | Leukopenia | Blood and lymphatic system disorders | NRE Cohort - CRPC 39.4mg (Castration-Resistant Prostate Cancer) | 3 | 51 | |
| other | Leukopenia | Blood and lymphatic system disorders | NRE Cohort - Ovarian 100mg | 5 | 60 | |
| other | Neutropenia | Blood and lymphatic system disorders | RDT All Cohorts | 35 | 526 | |
| other | Neutropenia | Blood and lymphatic system disorders | NRE Cohort - CRPC 100mg (Castration-Resistant Prostate Cancer) | 8 | 93 | |
| other | Neutropenia | Blood and lymphatic system disorders | NRE Cohort - CRPC 39.4mg (Castration-Resistant Prostate Cancer) | 3 | 51 | |
| other | Neutropenia | Blood and lymphatic system disorders | NRE Cohort - Ovarian 100mg | 7 | 60 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | RDT All Cohorts | 58 | 526 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | NRE Cohort - CRPC 100mg (Castration-Resistant Prostate Cancer) | 10 | 93 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | NRE Cohort - CRPC 39.4mg (Castration-Resistant Prostate Cancer) | 3 | 51 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | NRE Cohort - Ovarian 100mg | 9 | 60 | |
| other | Hypothyroidism | Endocrine disorders | RDT All Cohorts | 66 | 526 | |
| other | Hypothyroidism | Endocrine disorders | NRE Cohort - CRPC 100mg (Castration-Resistant Prostate Cancer) | 30 | 93 | |
| other | Hypothyroidism | Endocrine disorders | NRE Cohort - CRPC 39.4mg (Castration-Resistant Prostate Cancer) | 4 | 51 | |
| other | Hypothyroidism | Endocrine disorders | NRE Cohort - Ovarian 100mg | 15 | 60 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00940225/events